| Impax Laboratories, Inc | $6,400 million | The combined company will have a robust generics business that will rank as the 5th largest in the United States by gross revenue and a growing, high-margin specialty franchise. | Amneal Pharmaceuticals LLC | Merger | United States |
| Advanced Accelerator Applications (AAA) | $3,900 million | Integration of AAA would build on Novartis' expertise in diseases associated with NETs and introduce a new technology platform to Novartis providing an innovative approach to treating cancer. | Novartis | Acquisition | France |
| CureVac AG | $1,800 million | Development and commercialization of up to five potential cancer vaccine products based on CureVac's proprietary RNActive® technology | Eli Lilly and Company | Collaboration | Germany |
| CytomX | $1,500 million | Develop a CytomX Probody™ T-cell engaging bispecific against the Epidermal Growth Factor Receptor (EGFR), a highly validated oncology target expressed on multiple human cancer types. | Amgen | Collaboration | United States |
| MacroGenics, Inc. | $900 million | Development and commercialization of Anti-PD-1 Monoclonal Antibody MGA012 in all indications. | Incyte Corporation | Exclusive Worldwide Rights | United States |
| Kirin Holdings | $780 million | Amgen will own the product rights and remaining cash held by Kirin-Amgen. | Amgen (Amgen & Kirin Holdings (Kirin)) | Acquisition | Japan |
| KalVista Pharmaceuticals, Inc. | $760 million | Development of investigational plasma kallikrein inhibitors (KVD001) for treatment of diabetic macular edema DME | Merck | Collaboration | United States |
| Exactech | $625 million | Exactech is leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints | TPG Capital | Merger | United States |
| HemoShear Therapeutics, LLC | $470 million | To discover and develop novel therapeutics for liver diseases, including nonalcoholic steatohepatitis (NASH). | Takeda Pharmaceutical Company Limited | Partnership | United States |
| Warp Drive Bio, Inc. | $387 million | To advance novel classes of antibiotics to combat multi-drug-resistant bacterial infections. | Roche | Collaboration | United States |
| Apama Medical Inc | $300 million | To Strengthen Electrophysiology Portfolio and Expand into "Single-Shot" Balloon Pulmonary Vein Isolation Treatments for Patients with Atrial Fibrillation | Boston Scientific Corporation | Acquisition | United States |
| Poxel SA | $300 million | Development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China and eleven other Asian countries | Sumitomo Dainippon Pharma | Marketing & Development Rights | France |
| Bioprojet SCR | $270 million | Exclusive US right to develop, register and market the drug pitolisant | Harmony Biosciences, LLC | Exclusive US Right | France |
| Invendo Medical GmbH | $265 million | Invendo medical is a leading developer of sterile, single-use HD endoscopy products in the field of gastroenterology and gastrointestinal surgery. | Ambu A/S | Acquisition | Germany |
| Alector | $225 million | To advance innovative new therapies for Alzheimer's disease. | AbbVie | Collaboration | United States |
| JOTEC | $225 million | The combination of CryoLife and JOTEC will create a Company with a broad and highly competitive product portfolio focused on aortic surgery | CryoLife | Acquisition | Germany |
| NIH | $215 million | Partnership for Accelerating Cancer Therapies | AbbVie, Amgen,
Boehringer Ingelheim
Pharma GmbH & Co. KG,
Bristol-Myers
Squibb, Celgene Corporation,
Genentech, Gilead Sciences,
GlaxoSmithKline plc, Janssen Pharmaceutical Companies of Johnson & Johnson, Novartis, and Pfizer, Inc. | Partnership | United States |
| Vexim | $213 million | VEXIM, a French medical device company, specializes in the development and sale of vertebral compression fracture (VCF) solutions. | Stryker | Acquisition | France |
| Rotation Medical | $210 million | Rotation Medical Inc., is a developer of a novel tissue regeneration technology for shoulder rotator cuff repair | Smith & Nephew | Acquisition | United States |
| ADC Therapeutics | $200 million | To progress ADCT-301 and ADCT-402 currently in four clinical studies in important sub-types of lymphoma and leukemia into planned registrational trials in 2018 | Auven Therapeutics, Redmile, the Wild Family Office & AstraZeneca. | Financing | Switzerland |
| Karyopharm Therapeutics Inc. | $193.0 million | To develop and commercialize Selinexor and KPT-8602 in Japan and other countries in Asia | Ono Pharmaceutical Co., Ltd | Exclusive License Agreement | United States |
| Ablynx | $182.3 million | Ablynx NV is a late-stage clinical biopharmaceutical company utilising its proprietary Nanobody® platform to develop treatments for a broad range of therapeutic indications with an unmet medical need. | Undisclosed | IPO Funding | Belgium |
| Symbiomix Therapeutics | $150 million | Symbiomix Therapeutics is a biopharmaceutical company bringing innovative medicines to market for prevalent gynecologic infections that can have serious health consequences. | Lupin Inc. | Acquisition | United States |
| Cullinan Oncology | $150 million | Cullinan Oncology develops high value therapeutics geared towards dramatically improving the standard of care for those living with cancer. | Cambridge venture capital firm MPM Capita | Series A Financing | United States |
| Myovant Sciences | $140 million | To fund the ongoing Phase 3 development of its lead compound relugolix in uterine fibroids, endometriosis and prostate cancer. | NovaQuest Capital Management ("NovaQuest") and Hercules Capital, Inc. | Flexible Financing | United States |
| Universal Cells, Inc. | $124 million | To research, develop and commercialize a novel cell therapy for an undisclosed indication | Astellas Pharma Inc. | Exclusive Worldwide Rights | United States |
| OptiNose, Inc. | $120 million | OptiNose, Inc. is a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. | Jefferies and Piper Jaffray, BMO
Capital Markets and RBC Capital Markets | IPO funding | United States |
| Vios Medical | $102 million | Vios Medical, Inc. is a U.S. based medical technology company focused on utilizing medical-grade IoT sensors and Virtual Patient Care Services to optimize the management of patients | Murata Manufacturing | Acquisition | United States |
| GlaxoSmithKline | $96 million | Raxibacumab is a fully human monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax. | Emergent BioSolutions Inc | Product Acquisition | United Kingdom |
| Impact Biomedicines | $90 million | To advance the development, global supply chain build out, and future commercialization of fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor. | Oberland Capital | Structured Financing | United States |
| Roxwood Medical | $80 million | Roxwood Medical is developer of innovative solutions to tackle some of the most complex procedures in interventional cardiology. | BTG Plc | Acquisition | United States |
| KSQ Therapeutics | $76 million | To advance the development of drugs empowered by the unique biological insights of its proprietary CRISPRomics™ drug discovery engine. | Flagship Pioneering; Polaris Partners, ARCH Venture Partners, and Alexandria Equities | Financing | United States |
| Forty Seven Inc | $75 million | Expansion of ongoing clinical trials with CD47 antibody and initiation of new trials in combination with other immuno?oncology agents. | Wellington Management Company LLP, Clarus, Lightspeed Venture Partners, Sutter Hill Ventures and GV (Google Ventures). | Series B Financing | United States |
| Arsanis | $58 million | To get its mid-stage pneumonia fighting antibody through Phase II and down the road to a potential approval. | Undisclosed | IPO funding | United States |
| InflaRx | $55 million | To foster its clinical stage complement anti-C5a development programs | Bain Capital Life Sciences LP, Cormorant Asset Management LLC and RA Capital Management LLC | Series D Financing | Germany |
| Y-mAbs Therapeutics, Inc. | $50 million | To focus on bringing lead compounds, burtomab and naxitamab, through the final steps of the regulatory pathway towards approval | HBM Healthcare Investments | Equity Financing | United States |
| Visterra, Inc | $46.7 million | To advance pipeline of precision antibody-based biological medicines | Bill & Melinda Gates Foundation, MRL Ventures Fund, Vertex Venture Holdings Ltd Etc. | Series C Financing | United States |
| Eargo Inc | $45 million | To accelerate Eargo’s industry-leading product innovation, marketing and branding initiatives | Nan Fung Life Sciences & New Enterprise Associates, Charles and Helen Schwab, and Maveron | Series C Financing | United States |
| Gemini Therapeutics | $42.5 million | To develop precision therapeutics in ophthalmology and rare genetic diseases | Atlas Venture, Lightstone Ventures and OrbiMed | Series A Financing | United States |
| Shockwave Medical | $35 million | Expand commercialization and advance clinical development of the company’s Peripheral and Coronary Lithoplasty® Systems | Fidelity Management & Research Company & T. Rowe Price Associates, Inc | Financing | United States |
| Kymera Therapeutics LLC | $30 million | To advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases. | Atlas Venture, Lilly Ventures and Amgen Ventures | Series A Financing | United States |
| PnuVax | $29.4 million | To further develop and clinically evaluate PnuVax’s innovative pneumococcal conjugate vaccine. | Bill & Melinda Gates Foundation | Grant | Canada |
| TELA Bio | $25 million | To enhance commercial and clinical initiatives for distinct class of novel surgical implants for soft tissue repair | Pacira Pharmaceuticals | Equity Agreement | United States |
| Crystal Bioscience | $25 million | Crystal Bioscience is a leader in avian genetics and the generation of fully-human therapeutic antibodies | Ligand Pharmaceuticals | Acquisition | United States |
| Impact Biomedicines | $22.5 million | To Bring Fedratinib to Myelofibrosis Patients | Medicxi | Series A Financing | United States |
| Profectus BioSciences | $22.25 million | To develop multi-component vaccine for Ebola, Marburg, and Lassa viruses | National Institute of Allergy and Infectious Diseases | NIH Funding | United States |
| DURECT Corporation | $17.5 million | Agreement relates to intellectual property for RBP-7000, Indivior's investigational once-monthly injectable Risperidone product for schizophrenia | Indivior UK Limited | Patent Purchase Agreement | United States |
| Avita Medical | $16.9 million | US ReCell commercialisation for burn injuries and to further evaluate new indications | Undisclosed | Capital Raising | United States |
| Ionis Pharmaceuticals | $10 million | To initiate Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease. | Biogen | Collaboration | United States |
| AstraZeneca | $5 million | To conduct a Phase II study for the treatment of alpha-1 antitrypsin deficiency (“AATD”), a congenital orphan condition. | Mereo BioPharma | Exclusive License Agreement | United Kingdom |
| Carmel Biosciences | $0.5 million | To sell and market PREXXARTAN® (valsartan) oral solution in the United States and its territories. | Medicure Inc | Exclusive License to Sell & Market | United States |
| Arbutus | Undisclosed | To develop novel RNA-based personalized neoantigen immunotherapies for cancer patients | Gritstone | Collaboration & License Agreement | Canada |
| Dimension Therapeutics | Undisclosed | To create value by combining Dimension's innovative portfolio of assets and its advanced gene therapy platform with Ultragenyx's late-stage clinical, regulatory, and commercial expertise in the rare disease space. | Ultragenyx | Acquisition | United States |
| ABX GmbH | Undisclosed | Endocyte to focus resources on phase 3 registration trial of most advanced targeted radioligand therapy in development for prostate cancer, planned to initiate in first half 2018 | Endocyte, Inc. | Exclusive Worldwide Rights | Germany |
| Turnstone Biologics | Undisclosed | To license up to three of Turnstone's next-generation oncolytic viral immunotherapies | AbbVie | Research, Option & License Agreement | United States |
| Meiji Seika Pharma Co., Ltd. | Undisclosed | Development and commercialization of SPR994, with potential to be the first broad-spectrum oral carbapenem for use in adults. | Spero Therapeutics, Inc. | Exclusive License Agreement | Japan |
| Roivant Sciences | Undisclosed | Development partnership for a deprioritized investigational drug in an undisclosed indication. | AstraZeneca | Partnership | United States |
| Harpoon Therapeutics | Undisclosed | To incorporate Harpoon's tri-specific T-cell activating construct (TriTAC™) platform with AbbVie's research-stage immuno-oncology targets to develop novel cancer therapeutics | AbbVie | Collaboration | United States |
| Crestovo | Undisclosed | The combination of a potential first-in-class product candidate for recurrent C. difficile infections with a novel technology platform for developing Rationally-Selected Microbiota™ products. | Finch Therapeutics Group | Merger | United States |
| AstraZeneca | Undisclosed | To manufacture and market Zomig®(zolmitriptan) , Market Migraine Medication In Japan | Upsher-Smith Laboratories, LLC & Sawai Pharmaceutical Co., Ltd | Agreement | United Kingdom |
| Astellas Pharma Inc | Undisclosed | To discover antimalarial drugs | Medicines for Malaria Venture (“MMV”) | Screening Collaboration Agreement | Japan |
| TB Alliance & Astellas Pharma Inc. | Undisclosed | To discover anti- tuberculosis drugs | Global Health Innovative Technology Fund | Financing | United States |
| Mitsubishi Tanabe Pharma Corporation & Daiichi Sankyo Company, Limited | Undisclosed | Conduct a program called “JOINUS” (Joint Open INnovation of drUg repoSitioning) to discover new therapeutic drugs using drug-repositioning compound libraries. | Astellas Pharma Inc | Collaboration | Japan |
| Medicines Patent Pool (MPP) | Undisclosed | To expand access to bictegravir (BIC) upon regulatory approval in the United States. | Gilead Sciences, Inc. | License Agreement | Switzerland |
| MedImmune | Undisclosed | To enter clinical trial collaboration in early lung cancer | Incyte Corporation | Collaboration | United Kingdom |
| Applied BioMath, LLC | Undisclosed | For quantitative systems pharmacology modeling in immuno-oncology | Sanofi US | Collaboration | United States |
| ASPiRA Labs, a Vermillion company | Undisclosed | To provide coverage for its in vitro diagnostic test, OVA1®. | Joint Venture Hospital Laboratories, LLC ("JVHL"), QCA Health Plan of Arkansas, Inc. (d/b/a Qualchoice), Louisiana State Medicaid program, and Arizona State Medicaid Program | Agreement | United States |
| TESARO, Inc | Undisclosed | To conduct a proof-of-concept clinical trial evaluating the combination of oregovomab with ZEJULA® (niraparib) in the recurrent ovarian cancer setting | OncoQuest Inc. | Collaborative Agreement | United States |
| M2Gen | Undisclosed | ORIEN Avatar Program represents M2Gen's unique approach to accelerate the discovery and development of novel therapeutics for cancer | Bristol-Myers Squibb | Collaboration | United States |
| University of California San Francisco (UCSF) | Undisclosed | To evaluate Apexigen's immune activating antibody APX005M in combination with multimodality treatment of resectable esophageal and gastro-esophageal junction cancers | Apexigen, Inc | Collaboration | United States |
| Biophore India Pharmaceuticals Pvt Ltd | Undisclosed | To bring a generic version of Valeant's Cuprimine and other penicillamine based generic products to the U.S. market. | Amerigen Pharmaceuticals Limited | Collaboration | India |
| PAREXEL International Corp | Undisclosed | Form cloud technology alliance aimed at accelerating the pace of drug development | Microsoft | Collaboration | United States |
| Cannatech LLC | Undisclosed | For the acquisition of a 120-acre licensed industrial hemp farm in Amity, ME | Future Farm Technologies Inc. | Definitive Agreement | United States |
| Veritas Pharma Inc | Undisclosed | Purchase of share | Marapharm Ventures Inc | Purchase Agreement | Canada |
| Genentech | Undisclosed | Phase 1b/2 study for the treatment of gastric cancer with BL-8040 in combination with atezolizumab (TECENTRIQ®) | BioLineRx | Collaboration | United States |
| Inserm | Undisclosed | To study targeted nanotherapeutics for neurological disease | Genisphere LLC | Collaborative Research Agreement | France |
| iBio, Inc | Undisclosed | To support potential large-scale production of the Aethlon Hemopurifier® | Aethlon Medical, Inc | Collaboration | United States |
| QIAGEN | Undisclosed | To collaborate in bioinformatics for genetic diseases | CENTOGENE | Collaboration | Germany |
| Parata Systems | Undisclosed | To improve access to cutting edge technology | American Associated Pharmacies | Group Purchasing Agreement | United States |
| Catalent Pharma Solutions | Undisclosed | Formulation development and clinical manufacturing agreement of THX-TS01, a first-in-class, proprietary investigational drug candidate for the treatment of the symptoms of Tourette syndrome. | Therapix Biosciences Ltd | Agreement | United States |
| Grid Therapeutics | Undisclosed | To develop a novel targeted immuno-oncology therapy | Catalent Pharma Solutions | Multi-Year Agreement | United States |
| Medivir | Undisclosed | The exclusive worldwide rights to Medivir's research stage metallo-?-lactamase inhibitor (MBLI) program | AMR Centre Ltd | Exclusive Worldwide Rights | Sweden |
| Nostrum Laboratories Inc | Undisclosed | 5 ANDA's Three of the acquired assets are FDA approved and will be sold by Breckenridge under its label. Two of the assets are filed and pending with FDA with anticipated approval dates within the next 12 months | Breckenridge Pharmaceutical, Inc | Acquisition | United States |
| Eisai Inc | Undisclosed | To commercialize HALAVEN® (eribulin mesylate), LENVIMA® (lenvatinib), FYCOMPA® (perampanel) and INOVELON® (rufinamide) throughout Latin America | Grupo Biotoscana | Exclusive License Agreement | Japan |
| Univec, Inc | Undisclosed | To manufacture and distribute its medical cannabis transdermal patch for treatment and relief of approved medical conditions | AGRiMED Industries | Partnership | United States |
| Selectchemie | Undisclosed | License to register, market and sell Caspofungin Injection (systemic antifungal agent) in Saudi Arabia, the Gulf Countries, North Africa, and the rest of Middle East | Tabuk Pharmaceutical Manufacturing Company | License & Supply Agreement | Switzerland |
| SELLAS Life Sciences Group , Ltd | Undisclosed | Initiation of a phase 1/2 combination clinical trial with Galinpepimut-S and KEYTRUDA® (Pembrolizumab) across various indications expected in 1H, 2018 | Merck & Co., Inc., Kenilworth, N.J., USA | Supply Agreement | United States |
| Orexo | Undisclosed | Purchase Agreement of OX-MPI and to progress the candidate drug into proof-of-concept clinical trials. | Gesynta Pharma AB | Purchase Agreement | Sweden |
| Celltrion Healthcare | Undisclosed | For the distribution in Brazil of Herzuma®, the biosimilar Trastuzumab | Biomm SA | Distribution Rights Agreement | South Korea |
| Arcturus Therapeutics | Undisclosed | To develop and commercialize nucleic acid-based drug products for the treatment of Hepatitis B, using Arcturus’ UNA Oligomer chemistry and LUNAR™ lipid-mediated delivery platform | Janssen Pharmaceuticals, Inc (Johnson & Johnson) | Research Collaboration | United States |
| Microbiology & Quality Associates | Undisclosed | Acquisition of microbiology & quality associates in the San-Francisco bay area. | Analytical Lab Group | Acquisition | United States |
| Century Medical | Undisclosed | Acquisition of spinal-related business of Century Medical | Teijin Nakashima Medical | Acquisition of Spinal Related Business | Japan |
| Melvin Yahr International Parkinson's Disease Foundation | Undisclosed | To support the next generation Parkinson's treatment | Parkinson's Foundation, Inc | Merger | United States |
| Core Clinical, Inc. | Undisclosed | Medical imaging core lab based in Bucks County, PA. | Invicro | Acquisition | United States |
| Eqova Life Sciences | Undisclosed | A Medically-focused CBD company. | Grey Cloak Tech Inc | Acquisition | United States |
| Rhein Medical, Inc | Undisclosed | Provider of premium ophthalmic surgical instruments and devices. | Katena Products | Acquisition | United States |
| mProve Health Inc | Undisclosed | Provider of mobile technologies for life science companies. | Braket | Acquisition | United States |
| International Medical Management Corporation | Undisclosed | Japan’s largest supplier of unlicensed medicines | Clinigen | Acquisition | Japan |
| ResearchPoint Global | Undisclosed | A US-based contract research organization (CRO) with expertise spanning across all major therapeutic areas. | WuXi AppTec | Acquisition | United States |
| Surgical Process Institute | Undisclosed | German software company, a leading specialist for the standardization and digitalization of surgical workflows in the operating theatre. | Johnson & Johnson Medical GmbH | Acquisition | Germany |
| Cleveland HeartLab, Inc | Undisclosed | To identify and offer diagnostic services from Cleveland Clinic's innovations in inflammation and other areas of medicine | Quest Diagnostics | Acquisition | United States |
| KNOW Bio, LLC | Undisclosed | To treat viral malignancies with nitric oxide | Novan | Exclusive Worldwide Rights | United States |
| Evofem Biosciences, Inc | Undisclosed | To become a leading women’s health company that develops and commercializes novel products. | Neothetics, Inc | Merger | United States |
| Jazz Pharma | Undisclosed | LEUKOTAC® is an immunotherapy antibody with clinical benefits in steroidresistant acute Graft-versus-Host Disease. | Elsalys Biotech | Worldwide Rights | Ireland |
| SIMICON GMBH | Undisclosed | SIMICON manufactures both cleaning and biological indicators | Mesa Laboratories, Inc | Acquisition of All Outstanding Shares | Germany |
| Epiontis | Undisclosed | Next-generation European specialty laboratory providing immune monitoring services through a novel, patent-protected epigenetic platform. | Precision for Medicine | Acquisition | Germany |
| Promet Therapeutics, LLC | Undisclosed | Develops drug products to treat patients who have suboptimal and no treatment alternatives. | Heatwurx, Inc | Acquisition | United States |
| Aviragen Therapeutics | Undisclosed | Discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. | Vaxart, Inc | Merger | United States |
| Aquila BioMedical | Undisclosed | Innovative pre-clinical contract research organisation with expertise in immuno-oncology, immunology and multiplex histology. | Concept Life Sciences | Acquisition | United Kingdom |
| Shire PLC | Undisclosed | A clinical-stage mammalian manufacturing site in the United States | Lonza | Acquisition | Ireland |
| Humabs BioMed SA, Alnylam Pharmaceuticals, Inc., and Visterra, Inc. | Undisclosed | To address serious infectious diseases | Vir Biotechnology | Agreement | Switzerland |
